Moderna says its mRNA flu vaccine cleared early studies, but comparisons with other vaccines drive stock down
Moderna says that it’s on its way to having an mRNA vaccine against not one, but two different seasonal viruses.
The biotech released the first early data from its flu program Friday morning, announcing that all doses of the shot significantly boosted antibodies in younger and older adults without “significant safety findings.”
A 500-person Phase II will confirm dose levels and compare it to an approved flu vaccine, the company said, and preparations for a large pivotal trial are underway. Moderna said it is also advancing new designs that can have potentially broader coverage of different flu strains than current shots.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.